Palliative Endoscopic Esophageal Stenting for Malignant Esophageal Tumour Complications: A Clinical Case and Single Centre Experience in Latvia

• Published in: Proceedings of the Latvian Academy of Sciences. Section B, Natural Sciences Vol. 74; no. 2; pp. 125 - 130
• Main Authors: Straume, Zane, Proskurina, Anna, Strode, Zanda, Sekretarjovs, Jurijs, Skuja, Vita, Urķe, Anete, Lapiņa, Anita, Derovs, Aleksejs
• Format: Journal Article
• Language: English
• Published: Riga Sciendo 01.04.2020; De Gruyter Poland
• Subjects: Cancer; Dysphagia; Esophageal cancer; Esophagus; Fistulae; gastrointestinal cancer; Implants; Palliation; palliative care; Patients; Placement; Stenosis; Stents; tracheoesophageal fistula; Tumors; Latvia
• ISSN: 2255-890X; 1407-009X; 2255-890X
• DOI: 10.2478/prolas-2020-0020

Esophageal stenting is used in patients with malignant esophageal tumours to reduce dysphagia and inanition. The objective of this study was to analyse the main reasons for esophageal stenting in Rīga East Clinical University Hospital (RECUH) and their association with dysphagia and mortality. A cross-sectional study of all patients hospitalised in RECUH who received esophageal self-expanding metal stents (SEMS) from October 2013 to December 2015 was performed. A total of 29 patients, 24 (82.8%) male and 5 (17.2%) female, with mean age 63.7 ± 11.3 years, underwent the procedure. The most common indications for stenting were tumour-related stenosis (52.9%) and fistulae (17.6%). Mean time from establishing the diagnosis of esophageal cancer to stent placement was 338.6 days. Median survival after stenting was 4.8 months. A complex case of a patient requiring placement of three palliative stents illustrates the challenges of esophageal cancer care. Esophageal stent placement is an effective palliative method for treating tumour-related symptoms but carries risks of stent complications and fistula development over time. SEMS are being successfully used in cancer patient treatment in Latvia.